6-[(4-chlorophenyl)-hydroxy-(3-methylimidazol-4-yl)methyl]-4-[3-[(E)-ethoxyiminomethyl]phenyl]-1-methylquinolin-2-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 6-[(4-chlorophenyl)-hydroxy-(3-methylimidazol-4-yl)methyl]-4-[3-[(E)-ethoxyiminomethyl]phenyl]-1-methylquinolin-2-one
• 化学式: C₃₀H₂₇ClN₄O₃
• 分子量: 527.0
• InChiKey: KBVCBCFWHUZGEG-ATZGPIRCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS
  申请人：Pfizer Products Inc.

  公开号：EP1107962A1

  公开（公告）日：2001-06-20
• US6495564B1
  申请人：——

  公开号：US6495564B1

  公开（公告）日：2002-12-17
• [EN] QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS<br/>[FR] DERIVES DE QUINOLIN-2-ONE UTILES EN TANT QU'AGENTS ANTICANCEREUX
  申请人：PFIZER PROD INC

  公开号：WO2000012498A1

  公开（公告）日：2000-03-09

  Compounds of formula (1) and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R8 is H, -OR?12, -NR12R13, -NR12C(O)R13¿, cyano, -C(O)OR?13, -SR12, -(CR13R14)¿t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, or C1-C6 alkyl, wherein said heterocyclic and alkyl moieties are optionally substituted by 1 to 3 R6 substituents; R9 is -(CR13R14)t(imidazolyl) wherein t is an integer from 0 to 5 and said imidazolyl moiety is optionally substituted by 1 or 2 R6 substituents; provided that where R1 is not -(CR13R14)t(C3-C10 cycloalkyl), wherein t is an integer from 0 to 5, then R8 is triazolyl optionally substituted by 1 or 2 R6 groups, or at least one of R?3, R4 and R5¿ is -CH=NOR12 or -S(O)¿jR?12 wherein j is an integer from 0 to 2. The compounds of formula (1) are useful in the treatment of hyperproliferative disorders, such as cancer, in mammals. The invention also relates to pharmaceutical compositions containing the compounds of formula (1) and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula (1) to a mammal requiring such treatment.